AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
MindWalk Holdings Corp HYFT
News
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
United States